Distinguished in Multiple Myeloma

Dr. Majd Chahin

Hematology Oncology | Hematology | Oncology
100 Buckwalter Place Blvd Ste 130, 
Bluffton, SC 
Accepting New Patients
Distinguished in Multiple Myeloma
100 Buckwalter Place Blvd Ste 130, 
Bluffton, SC 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Majd Chahin is a Hematologist Oncology specialist and a Hematologist in Bluffton, South Carolina. Dr. Chahin is rated as a Distinguished provider by MediFind in the treatment of Multiple Myeloma. His top areas of expertise are Myelodysplastic Syndrome (MDS), Paget Disease of the Breast, Breast Cancer, and Colorectal Cancer. Dr. Chahin is currently accepting new patients.

His clinical research consists of participating in 8 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has participated in 1 clinical trial in the study of Multiple Myeloma.

Specialties
Hematology Oncology
Hematology
Oncology
Licenses
Internal Medicine in SC
Languages Spoken
English
Arabic
Castilian
Spanish
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Absolute Total Care South Carolina
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE-MEDICAID PLAN
Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Clover Health
  • INSURANCE PLAN
  • MEDICARE MAPD
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 5 Less Insurance Carriers -

Locations

100 Buckwalter Place Blvd Ste 130, Bluffton, SC 29910

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

Molecular Analysis for Therapy Choice (MATCH)
Molecular Analysis for Therapy Choice (MATCH)
Enrollment Status: Active_not_recruiting
Publish Date: October 01, 2025
Intervention Type: Procedure, Drug, Other, Biological
Study Drugs: Adavosertib, Afatinib, Binimetinib, Capivasertib, Copanlisib, Crizotinib, Dabrafenib, Dasatinib, Defactinib, Erdafitinib, FGFR Inhibitor AZD4547, Ipatasertib, Larotrectinib, Nivolumab, Osimertinib, Palbociclib, Pertuzumab, PI3K-Beta Inhibitor GSK2636771, Sapanisertib, Sunitinib, Taselisib, Trametinib, Trastuzumab, Ulixertinib, Vismodegib
Study Phase: Phase 2
A Phase II Trial of Trametinib With Docetaxel in Patients With KRAS Mutation Positive Non-Small Cell Lung Cancer (NSCLC) and Progressive Disease Following One or Two Prior Systemic Therapies
A Phase II Trial of Trametinib With Docetaxel in Patients With KRAS Mutation Positive Non-Small Cell Lung Cancer (NSCLC) and Progressive Disease Following One or Two Prior Systemic Therapies
Enrollment Status: Active_not_recruiting
Publish Date: September 22, 2025
Intervention Type: Other, Drug
Study Drugs: Docetaxel, Trametinib
Study Phase: Phase 2
Colorectal Cancer Metastatic dMMR/MSI-H Immuno-Therapy (COMMIT) Study: A Randomized Phase III Study of mFOLFOX6/Bevacizumab/Atezolizumab Combination Versus Single Agent Atezolizumab in the First-Line Treatment of Patients With Deficient DNA Mismatch Repair (dMMR)/Microsatellite Instability-High (MSI-H) Metastatic Colorectal Cancer
Colorectal Cancer Metastatic dMMR/MSI-H Immuno-Therapy (COMMIT) Study: A Randomized Phase III Study of mFOLFOX6/Bevacizumab/Atezolizumab Combination Versus Single Agent Atezolizumab in the First-Line Treatment of Patients With Deficient DNA Mismatch Repair (dMMR)/Microsatellite Instability-High (MSI-H) Metastatic Colorectal Cancer
Enrollment Status: Active_not_recruiting
Publish Date: September 05, 2025
Intervention Type: Other, Procedure, Drug, Biological
Study Phase: Phase 3
The National Myelodysplastic Syndromes Natural History Study
The National Myelodysplastic Syndromes Natural History Study
Enrollment Status: Active_not_recruiting
Publish Date: July 02, 2025
Intervention Type: Other
Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer
Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: January 13, 2025
Intervention Type: Other
Study Phase: Phase 3
Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients With High-Risk, Hormone Receptor-Positive and HER2/Neu Negative Breast Cancer
Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients With High-Risk, Hormone Receptor-Positive and HER2/Neu Negative Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: December 27, 2024
Intervention Type: Drug, Other
Study Drugs: Anastrozole, Everolimus, Exemestane, Goserelin Acetate, Letrozole, Leuprolide Acetate, Tamoxifen Citrate
Study Phase: Phase 3
A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for HER2 Negative Breast Cancer: The ABC Trial
A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for HER2 Negative Breast Cancer: The ABC Trial
Enrollment Status: Terminated
Publish Date: April 05, 2023
Intervention Type: Other, Drug
Study Drug: Aspirin
Study Phase: Phase 3
Implementation of a Prospective Financial Impact Assessment Tool in Patients With Metastatic Colorectal Cancer
Implementation of a Prospective Financial Impact Assessment Tool in Patients With Metastatic Colorectal Cancer
Enrollment Status: Completed
Publish Date: January 26, 2023
Intervention Type: Other
View 7 Less Clinical Trials
Similar Doctors
Distinguished in Multiple Myeloma
Dr. Ovidiu G. Negrea
Hematology Oncology | Oncology | Hematology
Distinguished in Multiple Myeloma
Dr. Ovidiu G. Negrea
Hematology Oncology | Oncology | Hematology

American Oncology Partners PA

16 Okatie Ctr Blvd S, Suite 2 201, 
Okatie, SC 
 (1.9 miles away)
912-692-2000
Languages Spoken:
English, Castilian, French, Romanian, Spanish
See accepted insurances
Accepting New Patients

Ovidiu Negrea is a Hematologist Oncology specialist and an Oncologist in Okatie, South Carolina. Dr. Negrea is rated as a Distinguished provider by MediFind in the treatment of Multiple Myeloma. His top areas of expertise are Thrombocytopenia, Iron Deficiency Anemia, Familial Colorectal Cancer, Lynch Syndrome, and Bone Marrow Aspiration. Dr. Negrea is currently accepting new patients.

Distinguished in Multiple Myeloma
Dr. Gary W. Thomas
Hematology Oncology | Hematology | Oncology
Distinguished in Multiple Myeloma
Dr. Gary W. Thomas
Hematology Oncology | Hematology | Oncology

South Carolina Cancer Specialists

45 Hospital Ctr Cmns, 
Hilton Head Island, SC 
 (12.4 miles away)
843-689-2895
Languages Spoken:
English, Castilian, Spanish
See accepted insurances
Accepting New Patients

Gary Thomas is a Hematologist Oncology specialist and a Hematologist in Hilton Head Island, South Carolina. Dr. Thomas is rated as a Distinguished provider by MediFind in the treatment of Multiple Myeloma. His top areas of expertise are Mantle Cell Lymphoma (MCL), Paget Disease of the Breast, Richter Syndrome, and Chronic Lymphocytic Leukemia (CLL). Dr. Thomas is currently accepting new patients.

Distinguished in Multiple Myeloma
Dr. Mark A. Taylor
Hematology Oncology | Hematology | Oncology
Distinguished in Multiple Myeloma
Dr. Mark A. Taylor
Hematology Oncology | Hematology | Oncology

Effingham Physician Practices, LLC

459 Hwy 119 S, Suite B, 
Springfield, GA 
 (24.4 miles away)
912-354-6187
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Mark Taylor is a Hematologist Oncology specialist and a Hematologist in Springfield, Georgia. Dr. Taylor is rated as a Distinguished provider by MediFind in the treatment of Multiple Myeloma. His top areas of expertise are Paget Disease of the Breast, Breast Cancer, Intraductal Papilloma, Myelodysplastic Syndrome (MDS), and Bone Marrow Aspiration. Dr. Taylor is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Chahin's expertise for a condition
ConditionClose
    View All 24 Distinguished Conditions
    View All 56 Advanced Conditions
    View All 155 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile